SCHEMBL18227144

SCHEMBL18227144

CN(C)c1ccc2cc(-c3c(F)cccc3F)c(N)nc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TERT O14746 2/20 0.49
▸ APP P05067 1/20 0.49
▸ APAF1 O14727 1/20 0.39
▸ FGFR1 P11362 2/20 0.39
▸ SRC P12931 1/20 0.39
▸ KCNH2 Q12809 2/20 0.38
▸ EGFR P00533 1/20 0.38
▸ MAT2A P31153 1/20 0.38
▸ NOS1 P29475 6/20 0.38
▸ PSMB5 P28074 2/20 0.37
▸ NOS2 P35228 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ JAK2 O60674 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ TYK2 P29597 1/20 0.35
▸ JAK3 P52333 1/20 0.35
▸ BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18227073 0.87 TERT (0.47) TERTAPPAPAF1KCNH2EGFR
SCHEMBL16739391 0.86 TERT (0.49) TERTAPPAPAF1FGFR1SRC
SCHEMBL16739384 0.81 TERT (0.46) TERTAPPFGFR1SRCPSMB5
SCHEMBL18227090 0.79 APP (0.47) TERTAPPAPAF1EGFRNOS1
SCHEMBL18226918 0.79 APP (0.47) TERTAPPAPAF1EGFRNOS1
SCHEMBL18226916 0.79 APP (0.47) TERTAPPAPAF1FGFR1SRC
SCHEMBL18227142 0.78 APP (0.50) TERTAPPAPAF1FGFR1SRC
SCHEMBL16739383 0.78 APP (0.50) TERTAPPAPAF1FGFR1SRC
SCHEMBL24800995 0.75 TERT (0.50) TERTAPPAPAF1FGFR1SRC
SCHEMBL18227076 0.75 DHFR (0.49) TERTAPPFGFR1SRCPSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160332971-A1 ARYLQUINOLINE, ARYLQUINOLONE AND ARYLTHIOQUINOLONE DERIVATIVES AND USE THEREOF TO TREAT CANCER UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2016-11-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332971-A1 ARYLQUINOLINE, ARYLQUINOLONE AND ARYLTHIOQUINOLONE DERIVATIVES AND USE THEREOF TO TREAT CANCER CASP4, PARP14, API5 TERT 1541/4885APP 2258/4885APAF1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback